Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings

NCT02777229 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

616

Enrollment

OTHER_GOV

Sponsor class

Conditions

HIV-1 Infection

Interventions

DRUG: Dolutegravir 50 mg
DRUG: Tenofovir disoproxil fumarate 300 mg / lamivudine 300 mg
DRUG: Efavirenz 400 mg

Sponsor

ANRS, Emerging Infectious Diseases

Collaborators

[object Object]
[object Object]